These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3058744)

  • 21. [Immunosuppressive treatment im multiple sclerosis].
    Mertin J
    Fortschr Med; 1980 Oct; 98(37):1431-6. PubMed ID: 6253370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
    Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A
    J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of multiple sclerosis.
    Rudick RA; Cohen JA; Weinstock-Guttman B; Kinkel RP; Ransohoff RM
    N Engl J Med; 1997 Nov; 337(22):1604-11. PubMed ID: 9371858
    [No Abstract]   [Full Text] [Related]  

  • 24. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G; Coustans M
    Pathol Biol (Paris); 2000 Mar; 48(2):114-20. PubMed ID: 10815287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
    Rudick RA
    J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL; Izquierdo-Ayuso G
    Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A changing treatment landscape for multiple sclerosis: challenges and opportunities.
    Piehl F
    J Intern Med; 2014 Apr; 275(4):364-81. PubMed ID: 24444084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.
    Kappos L; Patzold U; Dommasch D; Poser S; Haas J; Krauseneck P; Malin JP; Fierz W; Graffenried BU; Gugerli US
    Ann Neurol; 1988 Jan; 23(1):56-63. PubMed ID: 3278672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.
    Hommes OR; Weiner HL
    J Neurol Sci; 2004 Aug; 223(1):65-7. PubMed ID: 15261563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D
    Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 34. [Multiple sclerosis--current status of therapy].
    Reichel D; Kölmel HW
    Z Arztl Fortbild (Jena); 1995 May; 89(2):151-8. PubMed ID: 7610682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunosuppressive therapy in clinical practice].
    Frey FJ
    Schweiz Med Wochenschr; 1987 May; 117(21):810-5. PubMed ID: 3589636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Perspectives in Pediatric Neurology-Multiple Sclerosis.
    Narula S
    Curr Probl Pediatr Adolesc Health Care; 2016 Feb; 46(2):62-9. PubMed ID: 26669599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.